Receptors, Tumor Necrosis Factor, Type I
"Receptors, Tumor Necrosis Factor, Type I" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A tumor necrosis factor receptor subtype that has specificity for TUMOR NECROSIS FACTOR ALPHA and LYMPHOTOXIN ALPHA. It is constitutively expressed in most tissues and is a key mediator of tumor necrosis factor signaling in the vast majority of cells. The activated receptor signals via a conserved death domain that associates with specific TNF RECEPTOR-ASSOCIATED FACTORS in the CYTOPLASM.
MeSH Number(s)
D12.776.543.750.073.750
D12.776.543.750.705.852.760.597
D23.050.301.264.035.908
D23.101.100.110.912
Concept/Terms
Receptors, Tumor Necrosis Factor, Type I- Receptors, Tumor Necrosis Factor, Type I
- Antigens, CD120a
- CD 120a Antigen
- 120a Antigen, CD
- Antigen, CD 120a
- CD120a Antigen
- Antigen, CD120a
- CD120a Antigens
- Receptors, Tumor Necrosis Factor, Member 1A
- Tumor Necrosis Factor Receptor Type 1
- TNFR-I
- TNFR1
- TNFRSF1A (Tumor Necrosis Factor Receptor Superfamily, Member 1A)
- TNFRSF1A Receptor
- Receptor, TNFRSF1A
- Tumor Necrosis Factor Receptor 1A
- Tumor Necrosis Factor Receptor Superfamily, Member 1A
- Tumor Necrosis Factor Receptor Type I
- TNFR p60
Below are MeSH descriptors whose meaning is more general than "Receptors, Tumor Necrosis Factor, Type I".
- Chemicals and Drugs [D]
- Amino Acids, Peptides, and Proteins [D12]
- Proteins [D12.776]
- Membrane Proteins [D12.776.543]
- Receptors, Cell Surface [D12.776.543.750]
- Receptors, Death Domain [D12.776.543.750.073]
- Receptors, Tumor Necrosis Factor, Type I [D12.776.543.750.073.750]
- Receptors, Immunologic [D12.776.543.750.705]
- Receptors, Cytokine [D12.776.543.750.705.852]
- Receptors, Tumor Necrosis Factor [D12.776.543.750.705.852.760]
- Receptors, Tumor Necrosis Factor, Type I [D12.776.543.750.705.852.760.597]
- Biological Factors [D23]
- Antigens [D23.050]
- Antigens, Surface [D23.050.301]
- Antigens, Differentiation [D23.050.301.264]
- Antigens, CD [D23.050.301.264.035]
- Receptors, Tumor Necrosis Factor, Type I [D23.050.301.264.035.908]
- Biological Markers [D23.101]
- Antigens, Differentiation [D23.101.100]
- Antigens, CD [D23.101.100.110]
- Receptors, Tumor Necrosis Factor, Type I [D23.101.100.110.912]
Below are MeSH descriptors whose meaning is more specific than "Receptors, Tumor Necrosis Factor, Type I".
This graph shows the total number of publications written about "Receptors, Tumor Necrosis Factor, Type I" by people in Harvard Catalyst Profiles by year, and whether "Receptors, Tumor Necrosis Factor, Type I" was a major or minor topic of these publication.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 0 | 1 | 1 |
| 1996 | 0 | 4 | 4 |
| 1997 | 0 | 3 | 3 |
| 1998 | 0 | 1 | 1 |
| 1999 | 0 | 11 | 11 |
| 2000 | 0 | 4 | 4 |
| 2001 | 0 | 7 | 7 |
| 2002 | 0 | 7 | 7 |
| 2003 | 0 | 5 | 5 |
| 2004 | 1 | 6 | 7 |
| 2005 | 3 | 2 | 5 |
| 2006 | 3 | 3 | 6 |
| 2007 | 2 | 6 | 8 |
| 2008 | 5 | 6 | 11 |
| 2009 | 3 | 5 | 8 |
| 2010 | 4 | 5 | 9 |
| 2011 | 0 | 7 | 7 |
| 2012 | 5 | 4 | 9 |
| 2013 | 6 | 6 | 12 |
| 2014 | 3 | 3 | 6 |
| 2015 | 2 | 2 | 4 |
| 2016 | 1 | 2 | 3 |
| 2017 | 0 | 6 | 6 |
| 2018 | 2 | 3 | 5 |
| 2019 | 0 | 3 | 3 |
| 2020 | 1 | 3 | 4 |
| 2021 | 0 | 2 | 2 |
| 2022 | 1 | 2 | 3 |
| 2023 | 1 | 1 | 2 |
Below are the most recent publications written about "Receptors, Tumor Necrosis Factor, Type I" by people in Profiles.
-
Therapeutic potential of infliximab for pruritus in mice model of cholestasis induced by bile duct ligation: Possible involvement of IL-31. Int Immunopharmacol. 2023 Oct; 123:110806.
-
Prolonged hypoxia alleviates prolyl hydroxylation-mediated suppression of RIPK1 to promote necroptosis and inflammation. Nat Cell Biol. 2023 Jul; 25(7):950-962.
-
Assessment of systemic and gastrointestinal tissue damage biomarkers for GVHD risk stratification. Blood Adv. 2022 06 28; 6(12):3707-3715.
-
Acute Kidney Injury Associates with Long-Term Increases in Plasma TNFR1, TNFR2, and KIM-1: Findings from the CRIC Study. J Am Soc Nephrol. 2022 06; 33(6):1173-1181.
-
Distinctive Biomarker Features in the Endotheliopathy of COVID-19 and Septic Syndromes. Shock. 2022 01 01; 57(1):95-105.
-
Associations of Plasma Biomarkers of Inflammation, Fibrosis, and Kidney Tubular Injury With Progression of Diabetic Kidney Disease: A Cohort Study. Am J Kidney Dis. 2022 06; 79(6):849-857.e1.
-
Effects of the SGLT2 inhibitor canagliflozin on plasma biomarkers TNFR-1, TNFR-2 and KIM-1 in the CANVAS trial. Diabetologia. 2021 10; 64(10):2147-2158.
-
Utilizing an interim futility analysis of the OVAL study (VB-111-701/GOG 3018) for potential reduction of risk: A phase III, double blind, randomized controlled trial of ofranergene obadenovec (VB-111) and weekly paclitaxel in patients with platinum resistant ovarian cancer. Gynecol Oncol. 2021 05; 161(2):496-501.
-
An immune-based biomarker signature is associated with mortality in COVID-19 patients. JCI Insight. 2021 01 11; 6(1).
-
Association of Multiple Plasma Biomarker Concentrations with Progression of Prevalent Diabetic Kidney Disease: Findings from the Chronic Renal Insufficiency Cohort (CRIC) Study. J Am Soc Nephrol. 2021 01; 32(1):115-126.